The Lancet  
Mar 09, 2013  Volume 381  Number 9869  p777 – 874  e8
http://www.thelancet.com/journals/lancet/issue/current

Comment
The beginning of the end for serogroup B meningococcus?
Matthew D Snape, Andrew J Pollard

Preview
Widespread use of glycoconjugate vaccines against Haemophilus influenzae type b, Streptococcus pneumoniae, and serogroup C Neisseria meningitidis has resulted in a substantial decrease in childhood meningitis in industrialised countries, but the persisting threat posed by serogroup B Neisseria meningitidis (MenB) is an unwelcome anomaly. This organism’s external polysaccharide capsule is poorly immunogenic, sharing chemical and antigenic identity with human fetal neural-cell antigens, and is therefore unsuitable for use in a glycoconjugate vaccine.